Tuesday, July 16, 2024

Chemotherapy Treatment Simplified with New Injectable FOCINVEZ by Amneal Pharmaceuticals

Similar articles

Amneal Pharmaceuticals has introduced FOCINVEZ, a new injectable formulation designed to simplify treatment for patients undergoing chemotherapy. This product is notable for its polysorbate 80-free formulation, which eliminates the need for reconstitution or dilution, thereby enhancing convenience for healthcare providers.

FOCINVEZ is approved for use in adults and children aged six months and older, in combination with other antiemetic agents. It aims to prevent both acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin, as well as moderately emetogenic cancer chemotherapy (MEC). According to Sean McGowan, Amneal Pharmaceuticals’ Vice President of Biosimilars and Branded Oncology, this product is part of the company’s strategy to introduce complex, clinically impactful products that promote efficiency in oncology clinics and hospitals.

FOCINVEZ features a unique J-Code, J1434, issued by the Centers for Medicare & Medicaid Services, facilitating a smoother reimbursement process. Packaged in a 150mg/50mL (3mg/mL) vial, this ready-to-use injectable leverages an included vial hanger for direct administration, significantly reducing preparation time and the potential for dosage errors.

Treatment for Chemotherapy FOCINVEZ Simplifies Administration and Enhances Efficiency

FOCINVEZ simplifies the administration process by eliminating the need for dilution or reconstitution. The product is suitable for both adults and children over six months of age undergoing HEC or MEC. The unique J-Code (J1434) aids in a streamlined reimbursement process, easing financial management for healthcare facilities. Healthcare providers should be aware of potential adverse effects such as fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, and pain in extremities.

Amneal Pharmaceuticals, headquartered in Bridgewater, New Jersey, continues to expand its diverse portfolio, which includes over 280 pharmaceutical products predominantly catering to the US market. FOCINVEZ reflects its commitment to innovation and efficiency in medical treatments. By addressing the logistical challenges of chemotherapy administration, Amneal aims to enhance the overall healthcare experience for both providers and patients. This approach not only boosts operational efficiency within healthcare settings but also ensures that patients receive timely and accurate treatments, minimizing the risk of complications associated with chemotherapy-induced nausea and vomiting.

The launch of FOCINVEZ is a significant milestone for Amneal Pharmaceuticals as it underscores its ongoing dedication to developing advanced therapeutic solutions. The new formulation is designed to meet the evolving needs of oncology patients and healthcare providers by offering a ready-to-use solution that reduces the burden of preparation and administration time. This is particularly important in busy clinical environments where time and accuracy are critical.


FOCINVEZ’s J-Code and Pediatric Approval Enhance Oncology Care and Simplify Reimbursement

The inclusion of the J-Code J1434 also highlights Amneal’s foresight in addressing reimbursement challenges, making it easier for healthcare providers to manage the financial aspects of treatment. This can lead to better resource allocation and improved patient care, as providers can focus more on clinical outcomes rather than administrative tasks.

Moreover, FOCINVEZ’s approval for use in young children expands its utility, making it a versatile option in pediatric oncology. This is crucial as managing chemotherapy-induced nausea and vomiting in children requires careful consideration of dosing and administration methods. The product’s user-friendly design, combined with its clinical efficacy, positions it as a valuable tool in the oncology treatment arsenal.

You can follow our news on our Telegram and LinkedIn accounts.

In summary, FOCINVEZ by Amneal Pharmaceuticals represents a forward-thinking approach to oncology care. By simplifying treatment protocols and addressing key logistical challenges, it aims to improve the quality of life for patients undergoing chemotherapy. The product’s introduction to the market reinforces Amneal’s reputation as a leader in pharmaceutical innovation and a dedicated partner in the fight against cancer.


Resource: Amneal Pharmaceuticals, July 09, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article